Ted Haack

Vice President, LatticePoint Consulting

Role: Associate

Sites: CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Stream: Advanced Therapies

Ted Haack serves as a senior advisor to public and private life sciences companies based on his 30 years of experience in market access, commercialization, and financial reporting. His expertise includes business development/licensing,
portfolio planning, international patient access negotiations, health policy development, risk assessment, talent planning, and governance. Mr. Haack also has significant experience in intellectual property, including loss of exclusivity strategy in the generics and biosimilar spaces. His clients include a variety of companies launching their first product, expanding into new markets, and financial services firms investing in product revenue royalty streams.

Mr. Haack currently serves as an Independent Director and Audit Chair (2019-2021) on the board of Promethera Biosciences, SA (Private, Belgium, clinical-stage cell therapy). He was actively involved in Promethera’s planned March 2020 Tokyo Stock Exchange IPO process, including auditor engagement, TSE Examination Team interviews, and identification of diverse independent directors, as well as discussions with leading Japanese and US investment
banks, analysts, and the NASDAQ Center for Corporate Governance for a potential follow-on listing in New York. Mr. Haack has continued working with the board for the past 3.5 years post-bankruptcy reorganization, investor and partnership options, shareholder agreements and bridge financing opportunities.

In 2013, Mr. Haack was named as the first Head of Market Access for Genzyme’s Rare Disease Business Unit (US$3B) and was the Head of Market Access and Pricing & Reimbursement for Pfizer’s Primary Care Business Unit (US$21B)
prior to that. At Pfizer he led a multinational team of 60 colleagues (US$21 million budget), and was a member of the Primary Care Commercialization, Technical Review and Business Development leadership teams. His team was
responsible for optimizing Pfizer affiliate pricing and patient access negotiations, establishing the value of pipeline programs, and collaborating with partners at Boehringer Ingelheim, BMS, Eisai, and Janssen on various in-line and development products (Spiriva, Eliquis, Aricept, Alzheimer’s Disease). He was named 1 of 200 Great Managers at Pfizer out of approximately 20,000 managers worldwide based on achieving results and building talent.

Before Pfizer, Mr. Haack worked in international finance at Schering-Plough, and was an Audit Manager at Deloitte in the Parsippany, NJ and Frankfurt, Germany offices, where he audited a variety of public companies and their
international affiliates including SEC reporting, issue resolution, M&A due diligence and financial integration. He qualifies as an Audit Committee Financial Expert.

Mr. Haack serves on the Advisory Board of PharmaAcuity, a startup healthcare AI company, and was appointed to the Board of Director’s for the NACD Utah Chapter in December 2022, chairs the Program Committee and is an Audit
Committee member. He is an active member of the NACD and holds their Directorship Certification™ and the CERT Certificate in Cyber-Risk Oversight.

Mr. Haack holds a degree in accountancy from Villanova University, an MBA from New York University, and a Master of Arts in International Affairs from the Fletcher School at Tufts University. He is professionally fluent in German.